aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Revitope Oncology, founded to revolutionize cancer treatment, focuses on developing precise immunotherapies through advanced protein engineering. The company's core mission is to create safe and effective treatments for various cancers, aiming to bring hope and improve the quality of life for patients. Their flagship offering, the PrecisionGATE™ Technology Platform, enables the development of targeted therapies that elicit powerful immune responses against cancer cells.
Key figures associated with Revitope Oncology include leading scientists and biotech investors who support its innovative approach. The company has achieved significant milestones in its pipeline development, showcasing the potential of its PrecisionGATE™ platform. Revitope's impact lies in its promise to transform cancer treatment by making immunotherapies more precise and effective, thus addressing current challenges in oncology and offering new possibilities for patient care.
Operating Status
Active
Ownership Type(s)
Venture Capital, Equity
Main Product(s)
Cancer Immunotherapy
Technology
Biotech
Tags
Healthtech
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Revitope Oncology founded?
Revitope Oncology was founded in 2014.
Where is Revitope Oncology’s headquarters located?
Revitope Oncology’s headquarters is located in Cambridge, MA, US.
When was Revitope Oncology’s last funding round?
Revitope Oncology’s most recent funding round was for $8.5M (USD) in February 2016.
How many employees does Revitope Oncology have?
Revitope Oncology has 32 employees as of Feb 5, 2024.
How much has Revitope Oncology raised to-date?
As of July 05, 2023, Revitope Oncology has raised a total of $8.5M (USD) since Feb 8, 2016.
Add Comparison
Total Raised to Date
$8.5M
USD
Last Update Feb 8, 2016
Last Deal Details
$8.5M
USD
Feb 8, 2016
Series Unknown
Total Employees Over Time
32
As of Feb 2024
Revitope Oncology Address
700 Main Street
Cambridge,
Massachusetts
MA 02139
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts